NEWARK, NJ--(Marketwired - Apr 9, 2014) - BioNeutral Group, Inc. (OTCBB: BONU) (OTCQB: BONU) today announced that it has entered into Sales and Distribution Agreement with Menzer Ltd. for distribution of our OGIENE™ line of odor elimination and cleaning products in the United Kingdom, Europe and the Middle East.
This agreement is another component of our slate of channel partners that we are strategically aligning ourselves with. Initially Menzer will focus on sales of our OGIENE™ products for consumer use by distributing to chain store retailers. Menzer also plans to offer our OGIENE™ line commercially.
" We are delighted to be able to offer our customers in Europe the innovative technology OGIENE provides," said Scott Dougan, director of Menzer. "OGIENE™ will bring something new to the marketplace and we are confident the highly effective range of Odor eliminators and Multipurpose Cleansers will attract consumers across Europe."
"We are pleased to have Menzer on board to begin our initial commercialization effort at the consumer level," said Mark Lowenthal, President and CEO for BioNeutral. "Our OGIENE™ line of odor eliminators and cleaning products carry our unique and proprietary combinational chemistries offering superior performance that we feel will the consumer will respond to. Gaining access to store shelves in the UK and Europe should be a great start for us."
About Menzer Ltd.
Menzer Ltd is company registered in England and Wales located in Evesham, England focused on the sale and distribution of consumer and industrial specialty chemical products. Find Menzer at www.ogiene.co.uk
About BioNeutral Group, Inc.
Headquartered in Newark, New Jersey, BioNeutral Group, Inc., is a specialty technology-based life-science company that has developed a technology platform that neutralizes harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. BioNeutral's products, YGIENE™ and OGIENE™, kill germs and clean surfaces with a dramatic increase in speed and power over their rivals in the marketplace. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications. Its antimicrobial line of products under the YGIENE™ brand have been approved by the EPA for sale in the United States. For more information on BioNeutral, including a listing of company products, leadership and background please visit www.bioneutral.com .
Find us on Facebook: http://www.facebook.com/pages/BioNeutral-Grou...9938452393
Follow us on Twitter: http://twitter.com/bioneutralgroup
Forward-Looking Statements: This release contains certain "forward-looking statements" relating to the business of the Company and its subsidiary companies. These forward-looking statements are often identified by the use of forward-looking terminology such as "believes," "expects" or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those described in the Company's filings with the Securities and Exchange Commission. BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how the Company's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA has approved and registered the Company's data and findings specific to Ygiene-206. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene® and are available for sale in the United States.
CONTACT FOR THE COMPANY:
Mark Lowenthal
CEO
BioNeutral Group, Inc.
+1-973-577-8003
